BTS 71091
Latest Information Update: 24 Jan 2013
Price :
$50 *
At a glance
- Originator Abbott GmbH & Co. KG
- Class Obesity therapies
- Mechanism of Action Biogenic monoamine uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 24 Jan 2013 Discontinued - Preclinical for Obesity in United Kingdom (PO)
- 29 Aug 2003 No development reported - Preclinical for Obesity in United Kingdom (PO)
- 26 Jan 2000 Preclinical development for Obesity in United Kingdom (PO)